GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Return-on-Tangible-Asset

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Return-on-Tangible-Asset : -2,930.34% (As of Sep. 2015)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. OncoVista Innovative Therapies's annualized Net Income for the quarter that ended in Sep. 2015 was $-1.30 Mil. OncoVista Innovative Therapies's average total tangible assets for the quarter that ended in Sep. 2015 was $0.04 Mil. Therefore, OncoVista Innovative Therapies's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2015 was -2,930.34%.

The historical rank and industry rank for OncoVista Innovative Therapies's Return-on-Tangible-Asset or its related term are showing as below:

OVIT's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.36
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

OncoVista Innovative Therapies Return-on-Tangible-Asset Historical Data

The historical data trend for OncoVista Innovative Therapies's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Return-on-Tangible-Asset Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 510.25 -70.57 -117.87 -432.19 -4,667.89

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 829.22 -9,521.21 -3,211.59 -10,438.10 -2,930.34

Competitive Comparison of OncoVista Innovative Therapies's Return-on-Tangible-Asset

For the Biotechnology subindustry, OncoVista Innovative Therapies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Return-on-Tangible-Asset falls into.



OncoVista Innovative Therapies Return-on-Tangible-Asset Calculation

OncoVista Innovative Therapies's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2014 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=-2.544/( (0.096+0.013)/ 2 )
=-2.544/0.0545
=-4,667.89 %

OncoVista Innovative Therapies's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2015 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2015 )  (Q: Jun. 2015 )(Q: Sep. 2015 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2015 )  (Q: Jun. 2015 )(Q: Sep. 2015 )
=-1.304/( (0.028+0.061)/ 2 )
=-1.304/0.0445
=-2,930.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2015) net income data.


OncoVista Innovative Therapies  (OTCPK:OVIT) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


OncoVista Innovative Therapies Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines